CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 960 enrolled
Drug / intervention
CP-690,550 +3 moredrug
Likely dose
CP-690,550 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01309737
NCT01309737Phase 3Completed
CompareCT.gov

A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Pfizer·interventional·Posted Mar 7, 2011·Updated Sep 19, 2014

In Brief

A Phase 3 clinical trial evaluating CP-690,550 and Placebo/CP-690,550 for Psoriasis. Completed, enrolled 960 participants across 94 sites in 11 countries.

Detailed Summary

The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, Colombia, Germany, Hungary, Mexico, Poland, Puerto Rico, Serbia, Taiwan, Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2011
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.3 years ago

Interventions

CP-690,550drug

10 mg oral BID, Continuous treatment for 52 Weeks

CP-690,550drug

5 mg oral BID, Continuous treatment for 52 Weeks

Placebo/CP-690,550drug

0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)

Placebo/CP-690,550drug

0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)